Carl Weissman serves as President and CEO of Accelerator, a joint investment vehicle backed by a syndicate of venture capital firms, including OVP.  Accelerator invests in and actively manages emerging biotechnology companies.  Carl joined OVP as a venture partner in 2007 and focuses on the digital biology sector.  His investments include Allozyne and Viral Logic Systems Technology (VLST).  He serves on the Board of Directors for Allozyne, Accelerator and Fate, and is a Board Observer to CODA Genomics, NanoString, and Viral Logic Systems Technology (VLST).

Carl led the formation of Accelerator in 2003.  Accelerator has facilitated Series A investments in, and has managed or is currently managing the operations of, four OVP portfolio companies - Allozyne, Recodagen, Seredigm and VLST.  Allozyne and VLST have successfully raised Series B rounds ($55M and $30M, respectively) and have "graduated" from Accelerator. 

Prior to joining OVP, Carl was a Venture Partner at MPM Capital.  While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA.  Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company.  Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development.

Carl serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA), also the Board of the Oregon Translational Research and Drug Development Institute (OTRADI) and is President of the Board of Directors of Teens in Public Service.